Anxo Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 370.21 million compared to TWD 400.99 million a year ago. Net loss was TWD 39.32 million compared to net income of TWD 0.904 million a year ago.

Basic loss per share from continuing operations was TWD 0.82 compared to basic earnings per share from continuing operations of TWD 0.019 a year ago. Diluted loss per share from continuing operations was TWD 0.82 compared to diluted earnings per share from continuing operations of TWD 0.019 a year ago.